3-Year EPCORE NHL-1 Data Published Showing 53% Have Deep, Durable Remission

Why It Matters

These results validate epcoritamab as a long‑term therapeutic option for relapsed/refractory LBCL, potentially reshaping treatment algorithms and expanding the bispecific antibody market.

Key Takeaways

• 53% of complete responders progression‑free at three years
• Median complete response duration 36.1 months, longest over 43 months
• Cytokine release syndrome occurred in 51%, mostly grade 1‑2
• Phase 3 EPCORE DLBCL‑1 improved PFS by 26% versus chemo
• Epcoritamab gained accelerated FDA approvals for DLBCL and FL

Pulse Analysis

Bispecific antibodies have emerged as a pivotal class in hematologic oncology, linking T‑cells to malignant B‑cells to trigger targeted cytotoxicity. Epcoritamab, a subcutaneous CD3×CD20 construct, received its first accelerated FDA approval for relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) in 2023, followed by approval for follicular lymphoma in 2024. The drug’s mechanism—simultaneous engagement of CD3 on T‑cells and CD20 on tumor cells—offers an off‑the‑shelf alternative to autologous CAR‑T therapies, addressing manufacturing delays and accessibility concerns that have limited CAR‑T uptake.

The three‑year update from the EPCORE NHL‑1 trial underscores the durability of epcoritamab‑induced remissions. More than half of the complete responders remained progression‑free after three years, and median overall survival reached 18.5 months, with not‑reached survival for those in CR. Notably, 45% of evaluable patients achieved measurable residual disease negativity, suggesting deep molecular clearance. Safety signals stayed consistent; cytokine release syndrome affected just over half of participants, predominantly low‑grade, and infection rates aligned with expectations for heavily pre‑treated cohorts. These data provide compelling evidence that epcoritamab can sustain disease control even in patients refractory to multiple lines, including prior CAR‑T therapy.

From a commercial perspective, epcoritamab’s expanding label portfolio—now covering DLBCL, follicular lymphoma, and a frontline combination with lenalidomide and rituximab—positions it as a versatile asset in AbbVie’s oncology pipeline. The phase 3 EPCORE DLBCL‑1 trial’s 26% progression‑free survival improvement versus standard chemoimmunotherapy reinforces its competitive edge against other bispecifics and small‑molecule regimens. As payers evaluate cost‑effectiveness, the drug’s subcutaneous administration and manageable safety profile may drive broader adoption, potentially reshaping the standard of care for relapsed/refractory B‑cell malignancies.